

HERITAGE CANNABIS HOLDINGS CORP.

Interim Condensed Consolidated Financial Statements

Three and Nine Months Ended July 31, 2022 and July 31, 2021

(Stated in Canadian Dollars, Unaudited)



**NOTICE OF NO AUDITORS' REVIEW OF
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the interim condensed consolidated financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the interim condensed consolidated financial statements.

The accompanying unaudited interim condensed consolidated financial statements of Heritage Cannabis Holdings Corp. (the "Company") have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these interim condensed consolidated financial statements in accordance with standards established by the Chartered Professional Accountants of Canada ("CPA Canada") for a review of interim financial statements by an entity's auditor.

HERITAGE CANNABIS HOLDINGS CORP.

HERITAGE CANNABIS HOLDINGS CORP.

Interim Condensed Consolidated Financial Statements

Three and Nine Months Ended July 31, 2022 and July 31, 2021

	Page
Interim Condensed Consolidated Statements of Financial Position	1
Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)	2
Interim Condensed Consolidated Statements of Changes in Equity	3
Interim Condensed Consolidated Statements of Cash Flows	4
Notes to Interim Condensed Consolidated Financial Statements	5

HERITAGE CANNABIS HOLDINGS CORP.
Interim Condensed Consolidated Statements of Financial Position
As at July 31, 2022 and October 31, 2021
(Stated in Canadian Dollars, Unaudited)

	Notes	As at July 31, 2022	As at October 31, 2021
Assets			
Current			
Cash		\$ 5,098,689	\$ 3,763,577
Short-term investments	3	950,000	950,000
Sales tax recoverable		574,933	1,014,805
Accounts receivable	24(a)	7,525,991	4,773,285
Inventories	4	18,693,808	16,124,241
Prepaid expenses and deposits	5	1,935,404	2,347,740
Convertible promissory note receivable	6	-	259,481
Current portion of note receivable	7	227,620	-
Other current assets	8(i),15(b),21	212,991	48,831
		35,219,436	29,281,960
Note receivable	7	1,289,848	-
Other investments and deposits	8	442,591	438,678
Investment in associate	9	3,058,552	3,044,182
Intangible assets and goodwill	10	41,784,679	44,253,279
Property, plant and equipment	11	20,408,690	20,769,966
Total Assets		\$ 102,203,796	\$ 97,788,065
Liabilities			
Current			
Accounts payable and accrued liabilities	21(c),24(b)	\$ 15,123,328	\$ 7,785,461
Sales tax payable		802,261	276,032
Deferred revenue	12	1,156,256	240,705
Current portion of lease liabilities	13	87,235	79,359
Current portion of long-term debt	14	11,827,990	5,321
Current portion of contingent consideration payable	15	630,176	590,176
		29,627,246	8,977,054
Lease liabilities	13	663,074	729,744
Long-term debt	14	9,745	10,836,359
Contingent consideration payable	15	1,140,000	15,940,000
Derivative liabilities	16	2,515,149	1,478,469
Deferred tax liability	20	3,085,000	4,606,000
Total Liabilities		37,040,214	42,567,626
Equity			
Share capital	17	147,160,949	140,482,057
Contributed surplus	18	6,086,453	5,779,474
Accumulated other comprehensive loss	9,24(c)(i)	(88,075)	(197,307)
Accumulated deficit		(89,386,773)	(91,538,667)
Equity attributable to shareholders		63,772,554	54,525,557
Non-controlling interest	19	1,391,028	694,882
Total Equity		65,163,582	55,220,439
Total Liabilities and Equity		\$ 102,203,796	\$ 97,788,065
Going Concern (Note 1(a))			
Commitments (Note 22)			
Subsequent Events (Note 29)			

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Approved on behalf of the Board of Directors:

"Clint Sharples"

Director

"David Schwede", CEO

Director

HERITAGE CANNABIS HOLDINGS CORP.
Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

	Notes	Three Months Ended July 31,		Nine Months Ended July 31,	
		2022	2021	2022	2021
Gross Revenue	26	\$ 10,799,784	\$ 5,111,945	\$ 30,848,238	\$ 11,544,016
Excise taxes		(3,303,899)	(797,631)	(9,319,958)	(2,133,911)
Net Revenue		7,495,885	4,314,314	21,528,280	9,410,105
Cost of Sales	4	5,025,046	3,069,069	13,987,874	6,163,343
Gross Margin		2,470,839	1,245,245	7,540,406	3,246,762
General and Administrative Expenses					
Advertising, travel and promotion		203,282	610,309	579,277	1,150,097
Amortization and depreciation	4,10,11	1,243,398	3,578,515	3,788,053	7,947,406
Management and consulting fees	21	304,590	551,646	924,031	1,598,948
Occupancy, general and administrative		1,042,301	1,781,041	3,008,299	3,558,803
Professional fees		202,152	364,339	609,593	951,468
Share-based payments	18,21	463,290	979	676,434	355,026
Salaries, wages and benefits	21	1,931,034	1,449,068	5,049,358	3,333,080
		5,390,047	8,335,897	14,635,045	18,894,828
Other Income (Expense)					
Interest and other income	7	44,269	23,050	182,547	83,298
Interest and finance expense	13,14,16	(306,583)	(263,405)	(811,699)	(661,311)
Share of loss from investment in associate	9	(43,277)	(33,573)	(95,330)	(144,950)
Unrealized gain on other investments	8(i)	-	-	608,649	-
Unrealized gain (loss) on contingent consideration payable	15	(84,000)	(500,000)	8,331,429	(1,011,216)
Unrealized gain on derivative liabilities	16	443,971	246,906	206,083	604,256
		54,380	(527,022)	8,421,679	(1,129,923)
Income (Loss) Before Taxes		(2,864,828)	(7,617,674)	1,327,040	(16,777,989)
Income tax recovery					
Deferred income tax recovery	20	(71,000)	(912,000)	(1,521,000)	(2,004,000)
		(71,000)	(912,000)	(1,521,000)	(2,004,000)
Net Income (Loss)		\$ (2,793,828)	\$ (6,705,674)	\$ 2,848,040	\$ (14,773,989)
Other comprehensive income (loss) that may be reclassified to net income (loss)					
Gain (loss) on foreign currency translation	9,24(c)(i)	(5,499)	68,225	109,232	(225,553)
Comprehensive Income (Loss)		\$ (2,799,327)	\$ (6,637,449)	\$ 2,957,272	\$ (14,999,542)
Comprehensive Income (Loss) attributed to:					
Shareholders of the Company		\$ (3,461,775)	\$ (6,769,150)	\$ 2,261,126	\$ (15,539,618)
Non-controlling interest	19	662,448	131,701	696,146	540,076
		\$ (2,799,327)	\$ (6,637,449)	\$ 2,957,272	\$ (14,999,542)
Weighted average number of outstanding shares					
Basic	23	896,179,958	783,479,185	860,911,530	670,148,089
Diluted	23	896,179,958	783,479,185	895,454,052	670,148,089
Income (loss) per share					
Basic	23	\$ (0.00)	\$ (0.01)	\$ 0.00	\$ (0.02)
Diluted	23	\$ (0.00)	\$ (0.01)	\$ 0.00	\$ (0.02)

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

HERITAGE CANNABIS HOLDINGS CORP.
Interim Condensed Consolidated Statements of Changes in Equity
Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

	Notes	Number of Shares	Share Capital	Contributed Surplus	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Non-controlling Interest	Total
Balance at October 31, 2020		496,136,722	\$ 96,203,173	\$ 5,417,218	\$ 36,012	\$ (34,031,758)	\$ 640,186	\$ 68,264,831
Share-based payments - vesting of options	18(b)	-	-	4,333	-	-	-	4,333
Share-based payments - issuance of restricted shares		2,191,831	350,693	-	-	-	-	350,693
Restricted shares issued for debt and services		2,884,797	342,142	-	-	-	-	342,142
Shares issued for debt and services		665,049	76,555	-	-	-	-	76,555
Exercise of options		2,549,644	828,259	(578,259)	-	-	-	250,000
Shares issued as purchase consideration for Premium 5 acquisition		180,156,643	30,626,629	-	-	-	-	30,626,629
Issuance of units, net of issuance costs		98,900,000	11,902,943	598,392	-	-	-	12,501,335
Comprehensive income (loss) for the period		-	-	-	(225,553)	(15,314,065)	540,076	(14,999,542)
Balance at July 31, 2021		783,484,686	\$ 140,330,394	\$ 5,441,684	\$ (189,541)	\$ (49,345,823)	\$ 1,180,262	\$ 97,416,976
Balance at October 31, 2021		786,128,570	\$ 140,482,057	\$ 5,779,474	\$ (197,307)	\$ (91,538,667)	\$ 694,882	\$ 55,220,439
Share-based payments - vesting of options	18(b)	-	-	320,979	-	-	-	320,979
Share-based payments - issuance of shares	17(b)	7,109,090	355,455	-	-	-	-	355,455
Shares cancelled as consideration for debt assumed	17(b)	(933,333)	(126,000)	(14,000)	-	-	-	(140,000)
Shares issued as contingent consideration payment for Premium 5 acquisition	15(d),17(b)	107,142,857	6,428,571	-	-	-	-	6,428,571
Exercise of warrants	17(b),18(a)	29,809	20,866	-	-	-	-	20,866
Comprehensive income for the period	19	-	-	-	109,232	2,151,894	696,146	2,957,272
Balance at July 31, 2022		899,476,993	\$ 147,160,949	\$ 6,086,453	\$ (88,075)	\$ (89,386,773)	\$ 1,391,028	\$ 65,163,582

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

HERITAGE CANNABIS HOLDINGS CORP.
Interim Condensed Consolidated Statements of Cash Flows
Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

	Notes	Nine Months Ended July 31,	
		2022	2021
Operating Activities			
Net income (loss) for the period		\$ 2,848,040	\$ (14,773,989)
Items not affecting cash:			
Amortization and depreciation	10,11	3,788,053	7,947,406
Depreciation in cost of sales	10,11	-	251,815
Loss on disposal of property, plant and equipment	11	2,849	-
Capitalized depreciation recognized in cost of sales	4	103,341	561,929
Deferred income tax recovery	20	(1,521,000)	(2,004,000)
Non-cash items included in interest and other income	6,7	(56,707)	(3,740)
Non-cash interest and finance expense	16	204,993	342,035
Shares issued for debt and services		-	54,455
Share-based payments	17(b),18(b)	676,434	355,026
(Gain) on debt settlement		-	(5,900)
Share of loss from investment in associate	9	95,330	144,950
Unrealized loss (gain) on contingent consideration payable	15	(8,331,429)	1,011,216
Unrealized (gain) on derivative liabilities	16	(206,083)	(604,256)
Unrealized foreign exchange loss (gain)	9,24(c)(i)	(468)	6,046
Unrealized (gain) on other investments	8(i)	(608,649)	-
		(3,005,296)	(6,717,007)
Net changes in non-cash working capital, net of business combination:			
Sales tax recoverable		439,872	(920,255)
Accounts receivable		(2,752,706)	(2,938,998)
Inventories		(2,672,908)	(5,770,142)
Prepaid expenses and deposits		412,336	(1,856,737)
Other current assets		-	369,630
Other investments and deposits		(3,913)	(285,660)
Accounts payable and accrued liabilities		7,197,867	1,571,596
Sales tax payable		526,229	(29,919)
Deferred revenue		915,551	109,558
Cash Flows (Used in) Provided by Operating Activities		1,057,032	(16,467,934)
Investing Activities			
Acquisition of property, plant and equipment	11	(989,716)	(1,633,781)
Proceeds from disposal of property, plant and equipment	11	28,690	-
Issuance of note receivable	7	(1,460,761)	-
Proceeds from sale of other investment	8(i)	444,489	-
Maturity of convertible promissory note receivable	6	259,481	-
Cash acquired from business combination		-	1,281,341
Redemptions of short-term investments	3	-	3,600,000
Cash Flows (Used in) Provided by Investing Activities		(1,717,817)	3,247,560
Financing Activities			
Proceeds from exercise of options and warrants	17(b)	20,866	250,000
Proceeds from issuance of units, net of cash-settled issuance costs		-	12,501,335
Principal payments on lease obligation	13	(58,794)	(26,440)
Principal payments on long-term debt, net of cash-settled transaction costs	14	(3,945)	(4,675,780)
Proceeds from long-term debt, net of cash-settled transaction costs	14	1,000,000	5,888,567
Proceeds from convertible promissory note payable	16	1,037,770	-
Cash Flows Provided by Financing Activities		1,995,897	13,937,682
Net Increase in Cash During the Period		1,335,112	717,308
Cash, Beginning of Period		3,763,577	1,445,659
Cash, End of Period		\$ 5,098,689	\$ 2,162,967

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Supplementary information

Interest received		\$ 3,755	\$ 71,462
Interest paid	13,14	\$ 606,706	\$ 319,276
Shares and restricted shares issued for debt		\$ -	\$ 418,697
Shares issued for Premium 5 acquisition	17(b)	\$ 6,428,571	\$ 30,626,629
Shares cancelled as consideration for debt assumed	17(b)	\$ 140,000	\$ -
Non-cash share issuance costs		\$ -	\$ 598,392
Income taxes paid		\$ -	\$ -
Capitalized depreciation expense during the period		\$ -	\$ 172,287

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

Nature of business

Heritage Cannabis Holdings Corp. (the "Company") is a public company whose common shares trade on the Canadian Securities Exchange under the symbol "CANN". The Company was incorporated on October 25, 2007 in British Columbia, Canada, under the Business Corporations Act and commenced operations on November 1, 2007. On January 9, 2018, the Company changed its name to Heritage Cannabis Holdings Corp. The head office and principal address of the Company is Suite 600-77 Bloor Street West, Toronto, Ontario, Canada, M5S 1M2 and the registered office of the Company is located at Suite 1500-1055 West Georgia Street, Vancouver, British Columbia, Canada, V6E 4N7.

The Company is a vertically integrated cannabis business. In Canada, through its subsidiaries, Voyage Cannabis Corp. ("Voyage") and CannaCure Corporation ("CannaCure"), the Company holds licenses under the Cannabis Act (Canada) and its relevant regulations. Voyage, a holder of a cultivation, processing, medicinal and adult use, and cannabis oil sales licenses, as well as an industrial hemp license, operates out of a 15,500 square foot facility in Falkland, British Columbia. CannaCure, a holder of a cultivation, processing and medicinal and adult use sales license, as well as an industrial hemp license, operates out of a 122,000 square foot facility in Fort Erie, Ontario. Purefarma Solutions Inc. ("Purefarma"), a wholly-owned subsidiary, provides the Company with the experience and know-how necessary to manufacture, refine and formulate cannabis oils. CALYX Life Sciences Corp., a wholly-owned subsidiary, creates products and services aimed at providing an integrative approach to cannabinoid therapy for healthcare consumers and healthcare practitioners. On January 25, 2021, the Company acquired 100% of Premium 5 Ltd., a Canada-based recreational and medical cannabis company in high-quality full spectrum concentrates. In the United States, the Company operates under Opticann, Inc., a Colorado based oral and topical cannabinoid company.

1. Basis of presentation

(a) Going concern

Although the Company was awarded licenses and has invested resources into its business, the Company is not yet generating positive cash flows from operations and as such, it must rely, in part, on equity and debt financing to fund operations. To date, the Company's main source of funding has been the issuance of equity securities for cash through private placements to sophisticated investors, public offerings to institutional investors, and issuances of long-term debt.

These interim condensed consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern. This assumes that the Company will operate for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The Company incurred net loss of \$2,793,828 and generated net income of \$2,848,040 for the three and nine months ended July 31, 2022, respectively (for the three and nine months ended July 31, 2021 – net loss of \$6,705,674 and \$14,773,989, respectively), and had an accumulated deficit of \$89,386,773 as at July 31, 2022 (as at October 31, 2021 - \$91,538,667). The Company's ability to arrange additional financing in the future depends, in part, on the prevailing capital market conditions. These factors indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern.

The interim condensed consolidated financial statements do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and liquidate its liabilities, contingent obligations and commitments other than in the normal course of business and at amounts different from those in these interim condensed consolidated financial statements.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

1. Basis of presentation (continued)

(b) Statement of compliance

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34"). The accounting policies adopted in preparing these interim condensed consolidated financial statements are consistent with those applied in the Company's audited annual consolidated financial statements and notes as at and for the year ended October 31, 2021, except for the adoption of new accounting standards and policies described in Note 2. The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

These interim condensed consolidated financial statements do not conform in all respects to the requirements of International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") for annual financial statements. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the Company's audited annual consolidated financial statements and notes as at and for the year ended October 31, 2021.

These interim condensed consolidated financial statements were approved by the Board of Directors on September 27, 2022.

(c) Basis of measurement

These interim condensed consolidated financial statements have been prepared on the going concern basis, under the historical cost convention except for investment in Stanley Park Digital Ltd. ("SPD"), investment in 1186366 B.C. Ltd., convertible promissory note receivable, note receivable, acquisition-related contingent consideration payable, and derivative liabilities which are measured at fair value. These interim condensed consolidated financial statements have been prepared on an accrual basis except for cash flow information.

(d) Functional and presentation currency

These interim condensed consolidated financial statements are presented in Canadian dollars ("CDN") unless otherwise noted. The functional currency of Heritage US Holdings Corp., Heritage (US) Cali Corp., Heritage (US) Oregon Corp., Heritage (US) Colorado Corp., Opticann, Inc. and Endocanna Health, Inc. ("Endocanna") is the U.S. dollar ("USD"). The functional currency of the remaining entities is the Canadian dollar.

(e) Basis of consolidation

These interim condensed consolidated financial statements include the accounts of the Company and its subsidiaries, with intercompany balances and transactions eliminated on consolidation. Subsidiaries are those entities over which the Company has control, which exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity and is exposed to the variable returns from its activities. As of July 31, 2022, subsidiaries over which the Company has control are listed below.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

1. Basis of presentation (continued)

(e) Basis of consolidation (continued)

Subsidiaries	Ownership Percentage	Jurisdiction of Incorporation
1005477 B.C. Ltd.	100%	British Columbia, Canada
333 Jarvis Realty Inc.	100%	Ontario, Canada
5450 Realty Inc.	100%	British Columbia, Canada
CALYX Life Sciences Corp.	100%	British Columbia, Canada
CannaCure Corporation	100%	Ontario, Canada
Heritage Cannabis Exchange Corp.	100%	Ontario, Canada
Heritage (US) Cali Corp.	100%	California, United States
Heritage (US) Colorado Corp.	100%	Delaware, United States
Heritage US Holdings Corp.	100%	Delaware, United States
Heritage (US) Oregon Corp.	100%	Oregon, United States
Mainstrain Market Ltd. (Note 29)	75%	British Columbia, Canada
Opticann, Inc.	100%	Colorado, United States
Premium 5 Ltd.	100%	Alberta, Canada
Purefarma Solutions Inc.	100%	British Columbia, Canada
Voyage Cannabis Corp. (Note 29)	75%	British Columbia, Canada

Certain subsidiaries are controlled, indirectly, through other subsidiaries.

(f) Estimates and critical judgements made by management

The preparation of these interim condensed consolidated financial statements in conformity with IFRS requires management to make judgments and estimates that affect the reported amounts of assets and liabilities and disclosures of contingent assets and contingent liabilities at the date of the interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The interim condensed consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the interim condensed consolidated financial statements, and may require accounting adjustments based on future occurrences.

Revisions to accounting estimates are recognized in the period in which the estimate is revised and may affect both the period of revision and future periods. While management believes that the estimates are reasonable, actual results could differ materially from those estimates and may impact the future results of operations.

(g) COVID-19 Estimation Uncertainty

In March 2020, the World Health Organization declared the outbreak of the novel strain of coronavirus ("COVID-19"), a global pandemic. Government measures to limit the spread of COVID-19, including the closure of non-essential businesses, had an impact on the Company's operations from the second quarter of 2020. As at July 31, 2022, management did not identify any impairment indicators that suggest material impairment of the Company's assets or a significant change in the fair value of the assets due to COVID-19.

Due to the rapid developments and uncertainty surrounding COVID-19, it is not possible to predict the impact that COVID-19 will have on the Company's business, financial position and operating results in the future. In addition, it is possible that estimates in the Company's interim condensed consolidated financial statements will change in the near term as a result of COVID-19 and the effect of any such changes could be material, which could result in, among other things, impairment of long-lived assets including intangibles and goodwill. The Company is closely monitoring the impact of the pandemic on all aspects of its business.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

2. New accounting standards and pronouncements

(a) Amendment to IAS 1, Presentation of Financial Statements, Issued but not Yet Effective

IAS 1 was amended in January 2020 to address inconsistencies with how entities apply the standard over classification of current and non-current liabilities. The amendment serves to address whether, in the statement of financial position, debt and other liabilities with an uncertain settlement should be classified as current or non-current. The amendment is effective for annual reporting periods beginning on or after January 1, 2023. Earlier adoption is permitted. The Company will adopt this amendment as of the effective date, and is currently assessing the impacts of adoption.

(b) Amendment to IAS 37, Provisions, Contingent Liabilities and Contingent Assets, Issued but not Yet Effective

IAS 37 was amended in May 2020 to clarify the costs a company should include as the cost of fulfilling a contract when assessing whether a contract is onerous. The amendment is effective for annual reporting periods beginning on or after January 1, 2022. Earlier adoption is permitted. The Company will adopt the amendment as of the effective date, and is currently assessing the impacts of adoption.

(c) Amendment to IAS 16, Property, Plant and Equipment, Issued but not Yet Effective

IAS 16 was amended in May 2020 to prohibit deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognizes the proceeds from selling such items, and the cost of producing those items, in profit or loss. The amendment is effective for annual reporting periods beginning on or after January 1, 2022. Earlier adoption is permitted. The Company will adopt the amendment as of the effective date, and is currently assessing the impacts of adoption.

(d) Amendment to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors, Issued but not Yet Effective

In February 2021, the International Accounting Standards Board ("IASB") issued 'Definition of Accounting Estimates' to help entities distinguish between accounting policies and accounting estimates. The amendment is effective for annual reporting periods beginning on or after January 1, 2023. Earlier adoption is permitted. The Company will adopt the amendment as of the effective date, and is currently assessing the impacts of adoption.

3. Short-term investments

As at July 31, 2022, short-term investments consisted of \$950,000 (as at October 31, 2021 - \$950,000) in guaranteed investment certificates maintained with a Canadian chartered bank. The carrying value of these short-term investments approximates their fair value as at July 31, 2022 due to the short term to maturity. Of the total balance, \$50,000 is restricted and held as security against the Company's corporate credit card (as at October 31, 2021 - \$50,000).

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

4. Inventories

	As at July 31, 2022	As at October 31, 2021
Supplies and packaging materials	\$ 3,653,091	\$ 3,032,189
Dried cannabis and hemp	2,941,265	1,615,938
Manufacturing work in progress	2,624,630	3,250,178
Finished goods	9,386,194	8,101,748
Other	88,628	124,188
	\$ 18,693,808	\$ 16,124,241

During the three and nine months ended July 31, 2022, inventories expensed to cost of sales was \$5,025,046 and \$13,987,874, respectively (during the three and nine month ended July 31, 2021 - \$2,298,343 and \$4,906,563, respectively). As at July 31, 2022, \$nil (as at October 31, 2021 - \$103,341) of capitalized depreciation remained in inventories.

5. Prepaid expenses and deposits

	As at July 31, 2022	As at October 31, 2021
Inventory deposits	\$ 1,409,564	\$ 1,913,665
Prepaid insurance and consulting	98,664	65,577
Equipment deposits	145,950	40,971
Marketing	144,516	65,145
Other prepaid expenses	136,710	262,382
	\$ 1,935,404	\$ 2,347,740

6. Convertible promissory note receivable

In December 2019, the Company negotiated a promissory note from Empower Healthcare Assets Inc. ("Empower Health") for \$250,000, bearing interest at 2% per annum on the outstanding principal. The promissory note was due on demand and matured on December 31, 2021. The promissory note was guaranteed by Empower Health and Empower Clinics Inc. ("Empower Clinics"), an affiliated company of Empower Health. At the Company's option, the promissory note was convertible into the common shares of Empower Clinics based on the value of the common shares at the closing price the day before the conversion, or into the equity interest in the joint venture to be formed between the Company and Empower Health.

The convertible promissory note receivable was classified and measured at fair value through profit and loss ("FVTP"). As at October 31, 2021, the convertible promissory note receivable had a fair value of \$259,481. As at July 31, 2022, the convertible promissory note receivable was fully repaid in cash.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

7. Note receivable

On May 3, 2021, the Company entered into a consulting, purchase and branding agreement (“Agreement”), pursuant to which the Company agreed to provide an aggregate principal amount of up to \$1,000,000 USD (“Operating Loan”) to support two counterparties’ facility renovation and purchase of certain equipment and tools for the manufacture, distribution and sale of certain cannabis-based products. The Operating Loan bears an interest rate of 10% per annum and is payable with monthly equal payments over five years. Monthly payments, comprised of loan repayments and service fees as a percentage of the Company’s share of borrowers’ gross margin, shall begin thirty days after the first day the borrowers commence sale activities. The borrowers expect to commence sales in November 2022. As at July 31, 2022, the Company has disbursed \$1,460,761 CDN (equivalent to \$1,147,428 USD) in total.

The note receivable is classified and measured at FVTPL. The Company applied a discount rate of 10% in the calculation of the note receivable at fair value. No unrealized gain or loss was recognized as a result of changes in fair value of the note receivable during the nine months ended July 31, 2022.

The following is a continuity of the note receivable:

Balance at October 31, 2021	\$ -
Advances	1,460,761
Interest income	56,707
Balance at July 31, 2022	1,517,468
Less: current portion	(227,620)
Long-term portion	\$ 1,289,848

Future undiscounted principal payments for the note receivable, excluding variable service fees which are excluded from note receivable, are as follows:

	<1 year	2-5 years	> 5 years
Contractual cash flows	\$ 219,114	\$ 1,168,609	\$ 73,038

8. Other investments and deposits

	As at July 31, 2022	As at October 31, 2021
Refundable deposit for development costs	\$ 106,104	\$ 106,104
Investment in 118366 B.C. Ltd.	35,875	35,875
Investment in SPD (i)	-	-
Long-term deposits	300,612	296,699
	\$ 442,591	\$ 438,678

- (i) On April 30, 2020, the Company acquired 18% interest in SPD for total consideration of \$340,000. As at October 31, 2021, management determined the fair value of the investment in SPD as \$nil, given the investment was not in line with the Company’s core business and therefore provided negligible value to the Company. On March 30, 2022, the Company sold its interest in SPD for total cash proceeds of \$608,649. Immediately preceding such sale, the investment was revalued to \$608,649, with the full amount recognized as an unrealized gain in profit or loss. As at July 31, 2022, the Company received \$444,489 in cash, with the remaining proceeds of \$164,160 to be collected in the next quarter and included in other current assets in the statement of financial position.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

9. Investment in associate

On July 26, 2019, the Company acquired a 30% strategic interest in Endocanna, a company based in California, U.S.A. that develops saliva collection kits used in identifying genetic variants to facilitate cannabinoid formulation and dosing decisions.

A reconciliation of the carrying amount of the investment is detailed below:

Balance as at October 31, 2021	\$	3,044,182
Share of net loss		(95,330)
Foreign currency translation		109,700
Balance as at July 31, 2022	\$	3,058,552

10. Intangible assets and goodwill

	Licenses	Board relationships	Intellectual property	Brand	Goodwill	Total
Cost						
At October 31, 2021	\$ 29,208,072	\$ 1,034,000	\$ 7,250,000	\$ 9,530,500	\$ 4,858,330	\$ 51,880,902
At July 31, 2022	\$ 29,208,072	\$ 1,034,000	\$ 7,250,000	\$ 9,530,500	\$ 4,858,330	\$ 51,880,902
Accumulated amortization						
At October 31, 2021	\$ 4,621,026	\$ 79,037	\$ 1,769,794	\$ 1,157,766	\$ -	\$ 7,627,623
Additions	1,059,853	77,621	544,247	786,879	-	2,468,600
At July 31, 2022	\$ 5,680,879	\$ 156,658	\$ 2,314,041	\$ 1,944,645	\$ -	\$ 10,096,223
Net book value at						
October 31, 2021	\$ 24,587,046	\$ 954,963	\$ 5,480,206	\$ 8,372,734	\$ 4,858,330	\$ 44,253,279
Net book value at						
July 31, 2022	\$ 23,527,193	\$ 877,342	\$ 4,935,959	\$ 7,585,855	\$ 4,858,330	\$ 41,784,679

The details of individually material intangible assets are as follows:

Description	Carrying Amount		Remaining Amortization Period
	As at July 31, 2022	As at October 31, 2021	
CannaCure cultivation, processing and sales licenses	\$ 19,410,429	\$ 20,280,098	Approximately 16 years
Purefarma intellectual property	4,935,959	5,480,206	Approximately 6 years
Premium 5 board relationships	877,342	954,963	Approximately 9 years
Premium 5 brand	7,566,861	8,236,323	Approximately 9 years
Voyage processing and sales licenses	4,116,764	4,306,948	Approximately 16 years

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

11. Property, plant and equipment

	Equipment	Buildings and improvements	Land	Total
Cost				
At October 31, 2021	\$ 8,733,798	\$ 14,763,772	\$ 930,157	\$ 24,427,727
Additions	813,565	176,151	-	989,716
Disposals	(38,088)	-	-	(38,088)
At July 31, 2022	\$ 9,509,275	\$ 14,939,923	\$ 930,157	\$ 25,379,355
Accumulated depreciation				
At October 31, 2021	\$ 1,888,354	\$ 1,769,407	\$ -	\$ 3,657,761
Additions	712,461	606,992	-	1,319,453
Disposals	(6,549)	-	-	(6,549)
At July 31, 2022	\$ 2,594,266	\$ 2,376,399	\$ -	\$ 4,970,665
Net book value at				
October 31, 2021	\$ 6,845,444	\$ 12,994,365	\$ 930,157	\$ 20,769,966
Net book value at				
July 31, 2022	\$ 6,915,009	\$ 12,563,524	\$ 930,157	\$ 20,408,690

During the nine months ended July 31, 2022, the Company disposed of equipment, with a recognition of loss on disposal of \$2,849 in profit or loss.

Below is a reconciliation of changes in the right-of-use assets, which are included in the buildings and improvements balance based on the nature of the underlying assets:

	Right-of-use assets
Cost	
At October 31, 2021	\$ 832,800
At July 31, 2022	\$ 832,800
Accumulated depreciation	
At October 31, 2021	\$ 77,838
Additions	82,718
At July 31, 2022	\$ 160,556
Net book value at October 31, 2021	\$ 754,962
Net book value at July 31, 2022	\$ 672,244

As at July 31, 2022 and October 31, 2021, all of the Company's property, plant and equipment was domiciled in Canada.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

12. Deferred revenue

Deferred revenue represents the Company's outstanding performance obligations in relation to customer contracts as at July 31, 2022, which will be completed upon transfer of ownership (or deemed transfer) of extracts and as services are rendered on and before July 31, 2023. The entire period-end balance is classified as current.

As at July 31, 2022, the outstanding performance obligations require the Company to either (i) deliver crude cannabis extracts, and/or (ii) provide post extraction refinement, formulation and packaging services.

The following is a continuity of deferred revenue:

Balance as at October 31, 2021	\$	240,705
Revenue recognized from deferred revenue		(84,724)
Additions		1,000,275
Balance as at July 31, 2022	\$	1,156,256

13. Lease liabilities

In January 2021, as part of the Premium 5 acquisition, the Company acquired an office lease, with an escalating monthly lease payment of \$7,123 to \$7,700 until April 22, 2031. In March 2021, the Company entered into another lease for office space with an escalating monthly lease payment of \$5,811 to \$6,423 until April 30, 2026, the end of the initial term, with a subsequent renewal through April 30, 2031. The Company applied a discount rate of 10% in the calculation of lease liabilities. The Company did not enter into any new leases which would require a recognition of right-of-use assets and lease liabilities during the nine months ended July 31, 2022.

The following is a continuity of lease liabilities:

Balance as at October 31, 2021	\$	809,103
Interest expense		57,829
Lease payments		(116,623)
Balance as at July 31, 2022		750,309
Less: current portion		(87,235)
Long-term portion	\$	663,074

Future undiscounted lease payments for these leases, excluding certain operating expenses such as common area maintenance fees which are excluded from lease liabilities, are as follows:

	<1 year	2-5 years	> 5 years
Contractual cash flows	\$ 157,494	\$ 558,475	\$ 338,800

During the three and nine months ended July 31, 2022, the Company has recognized rent expenses of \$52,239 and \$141,070, respectively in profit or loss in relation to the short-term leases, low-value leases and variable lease payments which were excluded from the measurement of lease liabilities (during the three and nine months ended July 31, 2021 - \$14,091 and \$59,498, respectively).

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

14. Long-term debt

	As at July 31, 2022	As at October 31, 2021
(a) Term loan – non-interest bearing, principal-only payments of \$585 per month, 6-year term, maturing on January 18, 2025	\$ 15,474	\$ 19,419
(b) Term loan – comprised of three credit facilities for up to \$14,775,000, with two facilities bearing interest at Royal Bank of Canada prime rate plus 1.25% per annum and the remaining one bearing interest at 18% per annum, monthly interest-only payments, 16-month term, maturing on February 1, 2023	11,822,261	10,822,261
	11,837,735	10,841,680
Less: current portion	(11,827,990)	(5,321)
Long-term portion	\$ 9,745	\$ 10,836,359

- (a) The effective interest at a rate of 10% per annum has been imputed on the term loan, determined based on the Company's incremental cost of borrowing at the time of initial recognition. As at July 31, 2022, the face value of the term loan was \$17,558 (as at October 31, 2021 - \$22,825). The term loan was secured by an equipment with a carrying value of \$25,087 as at October 31, 2021. During the nine months ended July 31, 2022, the Company disposed of the underlying equipment. Consequently, the term loan became unsecured as at July 31, 2022.

- (b) On March 31, 2021, the Company, along with its subsidiaries CannaCure Corporation, 333 Jarvis Realty Inc., Voyage Cannabis Corp. and 5450 Realty Inc., (together the "Borrowers") entered into an 18-month loan agreement for \$7,000,000. The effective interest rate implicit in the term loan is 10%.

The term loan is secured by the following:

- (i) A promissory note in the amount of \$7,000,000;
- (ii) mortgages and assignments of rents over certain properties owned by the Company;
- (iii) an environmental indemnity agreement;
- (iv) an encumbrance and charge of all of the Borrowers' right, title and interest in the Borrowers' present and future personal property and assets by way of a general security agreement;
- (v) an assignment of proceeds from the Borrowers' sales;
- (vi) assignments and postponements of creditors' claims from creditors of the Borrowers;
- (vii) joint and several unlimited guarantees inclusive of assignments and postponements of creditors' claims from each of the guarantors, including five of the Company's remaining subsidiaries (together the "Guarantors");
- (viii) general security agreements from the Borrowers and Guarantors inclusive of serial specific registration on certain assets;
- (ix) a pledge by the Company, each of its subsidiaries and all the investees in which the Company holds interests;
- (x) an assignment of material contracts and insurance agreements granted by the Company and each guarantor; and
- (xi) solicitors' opinions for Borrowers.

On October 6, 2021, the Company amended the loan agreement by establishing three credit facilities for a maximum amount of \$14,775,000 (collectively the "Loan") as follows:

- (i) Facility 1: the initial loan is increased from \$7,000,000 to \$7,175,000, with the increase of \$175,000 to be used by the Company to pay to the lender an extension fee of \$175,000 to extend the due date to February 1, 2023;
- (ii) Facility 2: an additional loan \$2,600,000 will be advanced at the Royal Bank of Canada prime rate plus 1.25% per annum;
- (iii) Facility 3: a revolving line of credit up to maximum of \$5,000,000 shall be established at an interest rate of 18% per annum.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

14. Long-term debt (continued)

- (b) The Loan is due on February 1, 2023. If the Loan is repaid in its entirety on or before October 1, 2022, the lender will repay the \$175,000 extension fee for Facility 1 to the Company. As at July 31, 2022, the Company has received a total of \$11,822,261 in principal, with the remaining line of credit \$2,952,739 available for advance.

As part of the amendments, the Company also issued 10,000,000 warrants to the lender. Each warrant is exercisable into one Heritage common share at an exercise price of \$0.25 per share and has a term of 24 months expiring on October 8, 2023. See Note 18(a). These warrants were considered exchangeable into a fixed number of Heritage common shares, and thus were classified as equity.

Below is a reconciliation of changes in the carrying amount of the Loan:

Balance as at October 31, 2021	\$	10,822,261
Advances, net of cash-settled transaction costs		1,000,000
Interest expense		548,877
Interest payment		(548,877)
Balance as at July 31, 2022	\$	11,822,261

15. Contingent consideration payable

Balance as at October 31, 2021	\$	16,530,176
Payment made through issuance of common shares on contingent consideration issued in Premium 5 acquisition (Note 17(b))		(6,428,571)
Gain from remeasurement		(8,331,429)
Balance as at July 31, 2022		1,770,176
Less: current portion		(630,176)
Long-term portion	\$	1,140,000

- (a) Contingent consideration issued in Purefarma acquisition, equity-settled

On December 14, 2018, the Company acquired all the issued and outstanding shares of Purefarma Solutions Inc. ("Purefarma"). In connection with the acquisition, the Company is required to make certain pro-rata earn-out payments, payable in common shares, to former shareholders of Purefarma as additional purchase consideration. These payments are based on Purefarma's ability to meet certain extraction-related cumulative gross margin targets, as follows:

Upon Purefarma achieving a cumulative gross margin of \$25,000,000 for the period commencing on December 14, 2018 and ending on December 31, 2023, the Company will issue 2,500,000 common shares to the former shareholders of Purefarma.

Upon Purefarma achieving a cumulative gross margin of \$50,000,000 for the period commencing on December 14, 2018 and ending on December 31, 2023, the Company will issue 3,500,000 common shares to the former shareholders of Purefarma.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

15. Contingent consideration payable (continued)

(a) Contingent consideration issued in Purefarma acquisition, equity-settled (continued)

Upon Purefarma achieving a cumulative gross margin of \$75,000,000 for the period commencing on December 14, 2018 and ending on December 31, 2023, the Company will issue 4,500,000 common shares to the former shareholders of Purefarma; and

Upon Purefarma achieving a cumulative gross margin of \$100,000,000 for the period commencing on December 14, 2018 and ending on December 31, 2023, the Company will issue 5,500,000 common shares to the former shareholders of Purefarma; if Purefarma achieves such cumulative gross margin of \$100,000,000 before December 31, 2022, an additional 1,100,000 common shares will be issued to the former shareholders of Purefarma.

The total acquisition-date fair value of the equity-settled contingent consideration was apportioned in two. One portion was considered to be payable in a variable number of common shares and was therefore classified as a financial liability. The remainder was considered to be payable in a fixed number of common shares and was thus classified as equity. The balance being described in this note relates to the financial liability.

The period-end balance represents the probability-weighted discounted value of subsequent common share issuances expected to occur between August 1, 2022 and December 31, 2023, based on management's best estimate of the probability of Purefarma meeting each of the cumulative gross margin targets. Over the contractual term, the total cumulative earn-out could range from nil common shares (undiscounted value of \$nil) to 17,100,000 common shares (undiscounted value of \$3,078,000 at a share price of \$0.18 on the payout dates per Heritage common share based on the management's best estimates).

See Note 29 for subsequent settlement.

(b) Contingent consideration issued in Purefarma acquisition, cash-settled

The Company is required to make certain performance payments, in cash, to a company controlled by the former shareholders of Purefarma as additional purchase consideration. The remaining performance payment is based on 3% of extraction-generated gross margin for Purefarma's fiscal year 2022.

Prior to the acquisition during the Company's year ended October 31, 2019, the fiscal year end of Purefarma was December 31st. Purefarma's fiscal year end was then changed to coincide with that of the Company. As a result, a pro-rated catch-up payment may be required in December of 2022.

Additional performance payments may be required based on certain geographical scope parameters.

As at July 31, 2022, a balance of \$48,831 (as at October 31, 2021 - \$48,831) was outstanding from a corporation controlled by the former shareholders of Purefarma, including an active director of the Company. The director has the ability to exercise significant influence over the corporation in question. This balance is intended to be offset against the first payment made under the terms of the contingent consideration detailed above. The balance is unsecured, non-interest bearing, with no fixed terms of repayment and is included in other current assets in the interim condensed consolidated statement of financial position.

See Note 29 for subsequent settlement.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

15. Contingent consideration payable (continued)

(c) Contingent consideration issued in Voyage acquisition, cash-settled

In October of 2014, the Company entered into an agreement with the non-controlling shareholder of Voyage, the terms of which state that the non-controlling shareholder has the right to require the Company to purchase from its certain preferred shares in Voyage. The non-controlling shareholder has the ability to exercise this right upon Voyage meeting certain license procurement and the cumulative earnings before interest, taxes, depreciation and amortization ("EBITDA") milestones of \$1,500,000 and \$2,500,000, respectively. If all milestones were met and the non-controlling shareholder exercised its right, the Company would be required to purchase these preferred shares for total consideration of \$550,000.

During the year ended October 31, 2019, the first milestone of the license procurement was reached and the Company paid total proceeds of \$150,000 in cash to purchase 150,000 preferred shares in Voyage from the non-controlling shareholder.

As at July 31, 2022, management recognized the fair value of the contingent consideration payable in an amount of \$385,000, reflecting a high probability of meeting the remaining EBITDA milestones. The discount rate used was 15.8%, based on management's best estimates of cost of capital over the contractual term. If the discount rate decreased by 5%, the estimated fair value of the contingent consideration would increase by \$5,000. If the discount rate increased by 5%, the estimated fair value of the contingent consideration would decrease by \$4,000.

See Note 29 for subsequent settlement.

(d) Contingent consideration issued in Premium 5 acquisition, equity-settled

On January 25, 2021, the Company, through a wholly owned subsidiary, entered into a three-cornered amalgamation which resulted in the acquisition of all of the issued and outstanding shares of Premium 5 Ltd. The resulting amalgamated company changed its name to Premium 5 Ltd ("Premium 5").

As part of the acquisition, the Company is required to issue additional common shares to former shareholders of Premium 5 as additional purchase consideration. These payments are based on the Company's ability to achieve following targets:

- (a) Contingent performance payments payable in common shares, with a potential value of up to \$15,000,000, based on a fixed percentage of the excess net revenue over \$7,000,000 derived from certain products within the twelve months following the acquisition date ("First Performance Milestone"). The number of common shares to be issued shall reflect the intended dollar value of the consideration, with the value per share being the higher of the volume-weighted average price for the 10 trading days ended immediately prior to the close of the First Performance Period and \$0.14.
- (b) Contingent performance payment in the amount of \$5,000,000, payable in common shares, upon the Company's ability to achieve certain average gross margin target across all recreational products within the second twelve months following the acquisition date ("Second Performance Milestone"). The number of common shares to be issued shall reflect the intended dollar value of the consideration, with the value per share being the higher of the maximum allowable discount to market on the business day immediately prior to the close of the Second Performance Period and \$0.14.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

15. Contingent consideration payable (continued)

(d) Contingent consideration issued in Premium 5 acquisition, equity-settled (continued)

As at October 31, 2021, the Company recognized the fair value of the First Performance Milestone payment in an amount of \$15,000,000, which represented the maximum pay-out for such milestone given the Company has exceeded the milestone expectations by January 25, 2022. As at July 31, 2022, the Company issued 107,142,857 common shares as full payment for First Performance Milestone, with a fair value of \$6,428,571 determined based on the quoted market price on the date of issuance (see Note 17(b)). Immediately prior to such settlement, the Company revalued the First Performance Milestone to \$6,428,571, representing the fair value of common shares to be issued described above, with a recognition of gain from remeasurement of \$8,571,429 in profit or loss. The number of common shares issued reflected the intended maximum pay-out amount of \$15,000,000 divided by the deemed value of \$0.14 per share.

As at July 31, 2022, the Company re-valued the fair value of Second Performance Milestone payment using the Black-Scholes model with the following inputs, assumptions and result:

As at July 31, 2022	Performance Milestone 2
Option type	Cash-or-nothing
Gross margin	\$15,243,224
Cash payment	\$5,000,000
Exercise price	\$20,218,202
Time period (years)	0.49
Volatility	100%
Dividend yield	0.00%
Risk-free interest rate	2.96%
Calculated fair value of earnout	\$1,140,000

The following is a continuity of contingent consideration payable:

	Purefarma	Voyage	Premium 5	Total
Balance as at October 31, 2021	\$ 245,176	\$ 345,000	\$ 15,940,000	\$ 16,530,176
First Performance Milestone payment for Premium 5 acquisition (Note 17(b))	-	-	(6,428,571)	(6,428,571)
Unrealized loss (gain) from changes in fair value	-	40,000	(8,371,429)	(8,331,429)
Balance as at July 31, 2022	\$ 245,176	\$ 385,000	\$ 1,140,000	\$ 1,770,176

The Company's contingent consideration payable is measured at fair value based on unobservable inputs and is considered a level 3 financial instrument. Refer to Note 25.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

16. Derivative liabilities

	Heritage Cannabis Exchange Corp. (a)	Heritage Cannabis Holdings Corp. (b)	Total
Balance as at October 31, 2021	\$ 293,209	\$ 1,185,260	\$ 1,478,469
Addition	-	1,037,770	1,037,770
Interest expense	-	204,993	204,993
Unrealized gain from change in fair value	(169,318)	(36,765)	(206,083)
Balance as at July 31, 2022	\$ 123,891	\$ 2,391,258	\$ 2,515,149

(a) Heritage Cannabis Exchange Corp.

On October 6, 2020, the Company, through its wholly owned subsidiary Heritage Cannabis Exchange Corp. ("Purchaser Sub"), acquired all of the issued and outstanding shares of Opticann Inc. ("Opticann").

As part of the consideration for the acquisition of Opticann, Heritage Cannabis Exchange Corp. issued 7,919,493 warrants ("Class 1 Warrants"), exercisable for its Class A exchangeable shares at a price of \$0.20 per warrant for a period of 24 months from October 6, 2020, and 3,511,110 warrants ("Class 2 Warrants"), exercisable for its Class A exchangeable shares at a price of \$0.30 per warrant for a period of 36 months from October 6, 2020. The Class A exchangeable shares of the Purchaser Sub are redeemable and retractable into Heritage common shares on a 1:1 basis at the fair market value of a Heritage common share on the last business day prior to the redemption or retraction date at the option of the exchangeable shareholders ("Redemption/Retraction Price"). These warrants were considered to be exchangeable into a variable number of Heritage common shares and were therefore classified as financial liabilities measured at FVTPL.

As at July 31, 2022, the Company re-valued the warrant derivative liabilities using a level 3 valuation technique, as detailed in Note 25 with the following inputs, assumptions and results, respectively:

	Class 1 Warrants	Class 2 Warrants
Number of warrants issued	7,919,493	3,511,110
Risk-free interest rate	2.96%	2.96%
Expected life (years)	0.18	1.18
Expected annualized volatility	165%	120%
Expected annual dividend yield	0.00%	0.00%
Exercise price	\$0.20	\$0.30
Share price	\$0.04	\$0.04
Calculated fair value per warrant at period-end	\$0.001	\$0.032

Expected annualized volatility was estimated using the Company's average historical volatility for a time period equal to the Class 1 and 2 Warrants' remaining terms, respectively.

The following table summarizes warrant activities in Heritage Cannabis Exchange Corp. during the nine months ended July 31, 2022:

	Number of warrants	Weighted average exercise price
Balance as at October 31, 2021	11,430,603	\$ 0.23
Balance as at July 31, 2022	11,430,603	\$ 0.23

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

16. Derivative liabilities (continued)

(b) Heritage Cannabis Holdings Corp., the parent company

On October 18, 2021, the Company entered into a note and warrant purchase agreement (the “Agreement”) with two lenders, each to provide the Company \$750,000 USD for an aggregate funding of \$1,500,000 USD. The \$1,500,000 USD is to be disbursed in four tranches from October 18, 2021 through December 31, 2021. At closing of each disbursement, the Company will issue to the lender a convertible promissory note (each, a “Note” and together, the “Notes”) and a warrant (each, a “Warrant” and together, the “Warrants”).

The Notes mature in 24 months from the effective date and bear an interest rate of 15% per annum, which shall be paid in common shares of the Company (“Heritage Common Shares”) (such shares issuable as interest payment, the “Interest Shares”). The price per Interest Share shall be the greater of: (i) 90% of the volume weighted average price per Heritage Common Share for the five consecutive trading days preceding such issuance, and (ii) the minimum price per Heritage Common Share permitted pursuant to applicable securities laws and the requirements of the Canadian Securities Exchange (“CSE”). The Interest Shares shall be issued on a quarterly basis, beginning on January 18, 2022. The principal amount is due and payable upon maturity in cash or Heritage Common Shares (the “Conversion Shares”) at the option of Notes holders. The conversion price per Conversion Share shall be the greater of: (i) the closing market share price of the Heritage Common Shares on the trading day prior to a news release or the posting of notice to the CSE website, and (ii) \$0.07 CDN. As at July 31, 2022, no Interest Shares have yet been issued.

The Warrants issuable are exercisable for a period of 36 months from the issuance dates. Each Warrant is exercisable into Heritage Common Shares (the “Warrant Shares”), equal to 50% of the aggregate number of Conversion Shares that would be received upon the holder’s conversion of 100% of the aggregate amount of principal outstanding under the Note. Exercise price per Warrant Shares shall be the greater of: (i) the closing market share price of the Heritage Common Shares on the trading day prior to a news release or the posting of notice to the CSE website, and (ii) \$0.083 CDN.

Both the Notes and Warrants were considered to be exercisable into a variable number of Heritage Common Shares due to the variable conversion price, and therefore were classified together as a financial liability at FVTPL.

As at July 31, 2022, the Company received all tranches of \$1,500,000 USD (equivalent to \$1,855,270 CDN) in total principal, and issued a Note and Warrant upon the cash receipt per tranche. At initial recognition of each tranche, the Company allocated the proceeds received to the Note and the Warrant based on their relative fair value at the issuance date. The standalone fair value of the Note was calculated using the effective interest rate of 15% implicit in the Note. The standalone fair value of the Warrant was calculated using a level 3 valuation technique as detailed in Note 25. As at July 31, 2022, the Company revalued all the Notes at fair value, calculated as the greater of the amount payable in equity and the amount payable in cash if no conversion right is exercised. The Warrants were re-valued at fair value using the same valuation technique as that used for initial recognition with the following inputs, assumptions and results:

Tranche 1	As at October 31, 2021	As at July 31, 2022
Estimated number of Warrant Shares issuable	5,834,400	6,045,600
Risk-free interest rate	1.14%	2.96%
Expected life (years)	2.97	2.22
Expected annualized volatility	91%	104%
Expected annual dividend yield	0.00%	0.00%
Exercise price	\$0.08	\$0.08
Share price	\$0.065	\$0.040
Calculated standalone fair value per Warrant	\$363,637	\$100,435

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

16. Derivative liabilities (continued)

(b) Heritage Cannabis Holdings Corp., the parent company (continued)

Tranche 2	As at November 1, 2021, the issuance date	As at July 31, 2022
Estimated number of Warrant Shares issuable	3,317,142	3,435,000
Risk-free interest rate	1.14%	2.96%
Expected life (years)	3	2.25
Expected annualized volatility	91%	104%
Expected annual dividend yield	0.00%	0.00%
Exercise price	\$0.08	\$0.08
Share price	\$0.065	\$0.040
Calculated standalone fair value per Warrant	\$113,313	\$57,107

Tranche 3	As at November 30, 2021, the issuance date	As at July 31, 2022
Estimated number of Warrant Shares issuable	2,998,125	3,435,000
Risk-free interest rate	1.07%	2.96%
Expected life (years)	3	2.34
Expected annualized volatility	91%	103%
Expected annual dividend yield	0.00%	0.00%
Exercise price	\$0.08	\$0.08
Share price	\$0.080	\$0.040
Calculated standalone fair value per Warrant	\$136,271	\$58,245

Tranche 4	As at December 31, 2021, the issuance date	As at July 31, 2022
Estimated number of Warrant Shares issuable	815,014	824,400
Risk-free interest rate	1.02%	2.96%
Expected life (years)	3	2.42
Expected annualized volatility	91%	106%
Expected annual dividend yield	0.00%	0.00%
Exercise price	\$0.08	\$0.08
Share price	\$0.065	\$0.040
Calculated standalone fair value per Warrant	\$27,696	\$14,895

Expected annualized volatility was estimated using the Company's average historical volatility for a time period equal to the Warrants' remaining terms at valuation dates.

Below is a reconciliation of changes in the fair value of the Notes and the Warrants:

	Notes	Warrants	Total
Balance as at October 31, 2021	\$ 821,623	\$ 363,637	\$ 1,185,260
Additions	822,150	215,620	1,037,770
Interest expense	204,993	-	204,993
Unrealized (gain) loss from changes in fair value	311,810	(348,575)	(36,765)
Balance as at July 31, 2022	\$ 2,160,576	\$ 230,682	\$ 2,391,258

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

16. Derivative liabilities (continued)

(b) Heritage Cannabis Holdings Corp., the parent company (continued)

The following table summarizes warrant activities in the parent company for warrants classified as financial liabilities at FVTPL during the nine months ended July 31, 2022:

	Number of warrants
Balance as at October 31, 2021	1
Issuance	3
Balance as at July 31, 2022	4

17. Share capital

(a) Authorized share capital

The Company is authorized to issue an unlimited number of common shares without par value.

(b) Issued share capital

During the nine months ended July 31, 2022, the following share issuances took place:

On November 4, 2021, the Company issued 29,809 common shares as a result of warrant exercises at an exercise price of \$0.7 for total cash proceeds of \$20,866. The warrants were allocated \$nil value based on residual method upon issuance as part of a private placement, and therefore \$nil warrant reserve was transferred to share capital upon exercise.

On January 25, 2022, the Company issued 107,142,857 common shares to Premium 5 former shareholders as its First Performance Milestone payment in full (See Note 15(d)). The fair value of the common shares was measured at \$6,428,571, determined based on the quoted share price at the issuance date.

On June 3, 2022, the Company agreed to settle legal costs owing by certain Opticann former shareholders to a third party in the amount of \$140,000, which was included in the accounts payable and accrued liabilities in the statement of financial position as at July 31, 2022. In exchange, the Company cancelled 933,333 common shares held by these Opticann former shareholders. The original carrying amount of the cancelled common shares in the amount of \$126,000 was recorded as a reduction from share capital, with the difference of \$14,000 between the amount of liabilities assumed and the carrying amount of cancelled common shares aforementioned recorded as a decrease in contributed surplus. No gain or loss was recognized on this transaction.

On June 17, 2022, the Company issued 7,109,090 common shares to certain executives and consultants as compensation bonus, of which 3,745,454 common shares were issued to key management. The fair value of common shares issued was measured at \$355,455 determined based on the quoted share price of \$0.05 per share at the issuance date.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

18. Contributed surplus

(a) Warrants

Movements in the number of warrants outstanding during the nine months ended July 31, 2022 are as follows:

	Number of warrants	Weighted average exercise price
Balance as at October 31, 2021	134,438,700	\$ 0.27
Exercised (Note 17(b))	(29,809)	0.70
Expired	(18,585,891)	0.68
Balance as at July 31, 2022	115,823,000	\$ 0.21

The following table summarizes the warrants outstanding and exercisable as at July 31, 2022:

Expiry date	Number of warrants	Weighted average exercise price
March 17, 2023	98,900,000	\$ 0.21
March 17, 2023	6,923,000	0.14
October 8, 2024	10,000,000	0.25
	115,823,000	\$ 0.21

Of the 115,823,000 warrants outstanding, 6,923,000 are broker warrants and 108,900,000 are standard common share purchase warrants. Broker warrants are exercisable into units of the Company; in turn, each unit comprises one common share and either a whole or partial common share purchase warrant.

(b) Stock options

(i) Stock option plan details

The Company has adopted an incentive stock option plan, which provides that the Board of Directors of the Company may from time to time, in its discretion and in accordance with the Canadian Stock Exchange requirements, grant to directors, officers, employees and technical consultants to the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares of the Company. Options will be exercisable for a period to be determined by the Board of Directors, but not exceeding 10 years.

In connection with the foregoing, the number of common shares reserved for issuance to any technical consultant will not exceed two percent (2%) of the issued and outstanding common shares of the Company in any twelve-month period. The number of common shares reserved for issuance to individuals providing investor relation services will not exceed two percent (2%) of the issued and outstanding common shares of the Company in any twelve-month period. Furthermore, these options must vest over twelve months with a maximum of one quarter of the options vesting in any three-month period. Options may be exercised no later than 90 days following cessation of the optionee's position with the Company, provided that if the cessation of office, directorship, or technical consulting arrangement was by reason of death, the option may be exercised within a maximum period of one year after such death, subject to the expiry date of such option.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

18. Contributed surplus (continued)

(b) Stock options (continued)

Movements in the number of options outstanding during the nine months ended July 31, 2022 are as follows:

	Number of options	Weighted average exercise price
Balance as at October 31, 2021	24,763,440	\$ 0.19
Balance as at July 31, 2022	24,763,440	\$ 0.19

The following table summarizes the options outstanding and exercisable at July 31, 2022:

Expiry date	Number of options outstanding	Number of options exercisable	Weighted average exercise price
August 16, 2022 (Note 29)	2,000,000	2,000,000	\$ 0.10
November 15, 2022	80,000	80,000	0.14
January 22, 2023	700,000	700,000	0.59
March 19, 2023	861,000	861,000	0.54
April 30, 2023	850,000	850,000	0.35
August 20, 2023	254,964	254,964	0.20
April 10, 2025	892,476	892,476	0.20
February 8, 2024	3,750,000	3,750,000	0.34
September 20, 2024	1,500,000	1,500,000	0.36
September 17, 2026	13,875,000	4,625,000	0.10
	24,763,440	15,513,440	\$ 0.19

As at July 31, 2022, the weighted average remaining contractual life of all options outstanding was 2.85 years (as at October 31, 2021 – 3.60 years). The weighted average exercise price for exercisable options was \$0.25 (as at October 31, 2021 - \$0.25).

(i) Amounts arising from share-based payment transactions

During the three and nine months ended July 31, 2022, the Company recognized an expense of \$107,835 and \$320,979 respectively, relating to the vesting of options held by employees, directors, officers and consultants (during the three and nine months ended July 31, 2021 - \$979 and \$4,333, respectively).

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

19. Non-controlling interest

The net changes in non-controlling interest ("NCI") are as follows:

		Voyage	Mainstrain	Total
Balance as at October 31, 2021	\$	682,337	\$ 12,545	\$ 694,882
Share of income (loss)		743,849	(200)	743,649
Share of amortization of Voyage licenses acquired through business acquisition (Note 10)		(47,503)	-	(47,503)
Balance as at July 31, 2022	\$	1,378,683	\$ 12,345	\$ 1,391,028

See Note 29 for the Company's subsequent purchase of NCI.

20. Income taxes

The Company's combined Canadian federal and provincial statutory income tax rate is 26.5% for the nine months ended July 31, 2022. The rate is expected to apply for the full year.

Deferred tax assets and liabilities have been offset where they relate to income taxes levied by the same taxation authority and the Company has the legal right and intent to offset.

Balance at October 31, 2021	\$	4,606,000
Deferred income tax recovery		(1,521,000)
Balance at July 31, 2022	\$	3,085,000

21. Related party transactions and balances

All amounts either due to or from related parties, unless disclosed otherwise, are non-interest bearing, unsecured and due on demand. Transactions undertaken with related parties during the three and nine months ended July 31, 2022 and 2021 are as follows:

(a) Transactions with directors, officers and companies controlled by directors, officers and/or their families

	Three months ended July 31,	
	2022	2021
Management fees	\$ 15,000	\$ 52,000
Consulting fees	67,250	67,250
	\$ 82,250	\$ 119,250

	Nine months ended July 31,	
	2022	2021
Management fees	\$ 35,000	\$ 172,000
Consulting fees	201,750	324,061
	\$ 236,750	\$ 496,061

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

21. Related party transactions and balances (continued)

(b) Key management compensation

	Three months ended July 31,	
	2022	2021
Salary and short-term benefits	\$ 98,763	\$ 172,029
Share-based payments	224,578	-
	<u>\$ 323,341</u>	<u>\$ 172,029</u>

	Nine months ended July 31,	
	2022	2021
Salary and short-term benefits	\$ 296,290	\$ 333,537
Share-based payments	297,972	353,075
	<u>\$ 594,262</u>	<u>\$ 686,612</u>

During the three and nine months ended July 31, 2022, the Company issued 3,745,454 common shares to key management as compensation bonus with a fair value of \$187,273, determined based on the quoted share price at the issuance date. See Note 17(b).

(c) Related party balances

	As at July 31, 2022	As at October 31, 2021
Included in accounts payable and accrued liabilities	\$ 8,000	\$ 27,229
Included in other current assets (Note 15(b))	48,831	48,831

22. Commitments

As detailed in Note 16, the Company acquired Opticann on October 6, 2020. The remaining purchase consideration payable for the acquisition includes:

- (a) 100,000,000 Class B exchangeable shares of Purchaser Sub, which were issued upon acquisition and are redeemable and retractable, subject to conditions including Opticann's ability to meet certain cumulative gross margin targets within required time periods and to enter into distribution, supply, or collaboration agreements (or similar) with certain vendors, into Heritage Common Shares on a 1:1 basis at the Redemption/Retraction Price at the option of the exchangeable shareholders.
- (b) Contingent performance payments, payable in Heritage Common Shares, partly based on a fixed percentage of the funds invested in the Company in cash or assets up to certain amounts by certain vendors, partly upon the Company's ability to achieve certain cumulative sales or gross margin targets, and partly upon the acquisition of a supplier.

The acquisition was accounted for as an asset acquisition, given Opticann did not meet the definition of business at the acquisition date in accordance with IFRS 3. As at July 31, 2022 and October 31, 2021, no provision was recognized in relation to the above Class B exchangeable shares or contingent performance payments, given none of their payment milestones were met.

In addition, as consideration for the acquisition of Opticann license, the Company is committed to make the remaining payments, including:

- (a) \$2,600,000 USD payable upon the Company's achievement of certain milestones, including its receipt of first purchase order for certain goods and reaching \$2,000,000 USD and \$1,000,000 CDN sales of certain goods, respectively;
- (b) Royalty payment of 20% on all gross margins from the sale of certain goods, payable quarterly;

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

22. Commitments (continued)

- (c) Additional milestone payments, calculated as 10% of the value of any upfront milestone payments received by the Company for certain agreements with certain parties and 15% of the gross margin received on net sales as a result of certain agreements between the Company and certain parties; and
- (d) Dedication of a minimum 11% of net sales per year for marketing activities, which commences at the same time as the purchase right noted below.

The Company also has a right to purchase at least USD \$27,500,000 of certain goods from a supplier over 3 years from the first day of the month in which the Company received the purchase order for certain goods from any customer.

As at July 31, 2022 and October 31, 2021, none of the payment milestones were met and, therefore, no provision was recognized.

23. Income (loss) per share

Basic income (loss) per share amounts are calculated by dividing the net income (loss) attributable to common shareholders for the periods by the weighted average number of common shares outstanding during the periods.

Below is the calculation of basic and diluted income (loss) per share for the nine months ended July 31, 2022 and 2021:

Basic income (loss) per share	Nine months ended July 31,	
	2022	2021
Issued shares, beginning of period	786,128,570	496,136,722
Weighted average issuances	74,782,960	174,011,367
Weighted average common shares, end of period	860,911,530	670,148,089
Net income (loss) attributed to common shareholders of the Company	\$ 2,151,894	\$ (15,314,065)
Basic income (loss) per share	\$ 0.00	\$ (0.02)

Diluted income (loss) per share	Nine months ended July 31,	
	2022	2021
Weighted average common shares used in the computation of basic income (loss) per share, end of period	860,911,530	670,148,089
Dilutive effect of warrants exercised (Note 17(b))	328	-
Dilutive effect of equity-settled contingent consideration payment (Note 17(b))	33,359,497	-
Dilutive effect of convertible interest payable (Note 16(b))	1,182,697	-
Weighted average common shares used in the computation of diluted income (loss) per share, end of period	895,454,052	670,148,089
Net income (loss) attributed to common shareholders of the Company	\$ 2,151,894	\$ (15,314,065)
Diluted income (loss) per share	\$ 0.00	\$ (0.02)

The basic and diluted loss per share amounts are the same for the three months ended July 31, 2022 and July 31, 2021, as there were no instruments that had a dilutive effect.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

24. Financial instruments

The Company is exposed to risks that arise from its use of financial instruments. This note describes the Company's objectives, policies and processes for managing those risks and the methods used to measure them. Further quantitative information pertaining to these risks is presented throughout these interim condensed consolidated financial statements.

There have been no substantive changes in the Company's exposure to financial instrument risks, its objectives, policies and processes for managing those risks, or the methods used to measure them since October 31, 2021, unless otherwise stated.

(a) Credit risk

Credit risk is the risk of a potential loss to the Company if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company has moderate exposure to credit risk from its cash, short-term investments, accounts receivable, and note receivable. The risk exposure is limited to their carrying amounts at the statement of financial position date. The risk for cash and short-term investments is mitigated by holding these balances with highly-rated Canadian financial institutions. The Company therefore does not expect any credit losses on its cash and short-term investments.

The Company's accounts receivable balance consists of the following:

	As at July 31, 2022	As at October 31, 2021
Trade accounts receivable from customers	\$ 7,549,106	\$ 4,621,574
Expected credit losses	(248,699)	(91,194)
Net trade receivables	7,300,407	4,530,380
Interest and other receivables	225,584	242,905
	<u>\$ 7,525,991</u>	<u>\$ 4,773,285</u>

The Company provides credit to certain customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Credit risk for customers is assessed on a case-by-case basis and a provision is recorded where required. As at July 31, 2022, the Company identified certain accounts that may result in a credit loss on its accounts receivable, for which expected credit losses were recognized.

The Company has assessed that there is a concentration of credit risk, as 76% of the Company's net trade accounts receivable is due from three customers as at July 31, 2022 (as at October 31, 2021 - 77% of the balance due from three customers).

An analysis of the aging of trade accounts receivable (net of allowance) is as follows:

	As at July 31, 2022	As at October 31, 2021
Current (30 days or less)	\$ 3,902,667	\$ 2,397,231
31-60 days	2,599,132	1,558,194
61-90 days	132,391	93,189
Greater than 90 days	666,217	481,766
	<u>\$ 7,300,407</u>	<u>\$ 4,530,380</u>

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

24. Financial instruments (continued)

(b) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet the financial obligations associated with its financial liabilities as they come due. The Company manages liquidity risk through the management of its capital structure. As at July 31, 2022, the Company had working capital of \$5,592,190 (as at October 31, 2021 – \$20,304,906). The Company does not yet have positive cash flows from operations and as such, the Company may be dependent upon the issuance of new equity and/or debt to advance its production efforts and meet its financial obligations. If equity or debt financing is required, failure to obtain such financing on a timely basis may cause the Company to postpone, reduce or terminate its production plans.

The Company has the following undiscounted contractual obligations subject to liquidity risk, in addition to those relating to lease liabilities disclosed in Note 13:

	<1 year	2-5 years	> 5 years
Accounts payable and accrued liabilities	\$ 15,123,328	\$ -	\$ -
Long-term debt	11,829,284	10,535	-
Derivative liabilities with cash settlement option (Note 16(b))	-	1,923,600	-
Contingent consideration payable	645,176	-	-
Total	\$ 27,597,788	\$ 1,934,135	\$ -

(c) Market risk

(i) Foreign currency risk

Foreign currency risk is the risk that a variation in exchange rates between the Canadian dollar and other foreign currencies will affect the Company's operations and financial results. The Company is exposed to this risk on its investment in Endocanna (Note 9), an associate that bears the U.S. dollar as its functional currency. The Company is required to translate the financial position and operating results of Endocanna into Canadian dollars and to recognize its share of the resulting translation gain or loss in other comprehensive income or loss. The Company is further exposed to the foreign currency risk through Opticann, a wholly owned subsidiary operating in United States (Note 1(e)), and through its derivative liabilities denominated in USD (Note 16(b)). As at July 31, 2022 and October 31, 2021, the Company has not entered into any hedging agreements to mitigate foreign currency risk. As such, the Company's financial position and financial results may be adversely affected by the unfavorable fluctuations in foreign currency exchange rates.

The following table provides a summary of financial assets and liabilities denominated in USD:

	As at July 31, 2022	As at October 31, 2021
Cash	\$ 4,997	\$ 3,579
Accounts receivable	659	659
Accounts payable and other liabilities	13,652	39,484
Investment in associate	2,385,023	2,459,747
Derivative liabilities	1,664,478	663,526

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

24. Financial instruments (continued)

(c) Market risk (continued)

(i) Foreign currency risk (continued)

A 10% strengthening of the Canadian dollar against the foreign currencies listed above would increase other comprehensive loss by \$137,064 for the nine months ended July 31, 2022 (for the year ended October 31, 2021 - \$382,481). A 10% weakening of the Canadian dollar against the foreign currencies listed above would result in an equal, but opposite effect.

(ii) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's short-term investments and note receivable earn fixed rates of interest in the range from 0.7% to 1.05% per annum and 10% per annum respectively. The Company is exposed to this risk on its long-term debt, part of which bears interest at a Canadian prime rate plus 1.25% per annum as detailed in Note 14. As at July 31, 2022, the Company had no hedging agreements in place.

(iii) Price risk

Price risk is the risk of variability in fair value due to movements in equity or market prices. As at July 31, 2022 and October 31, 2021, the Company is exposed to this risk on its contingent consideration payable in Heritage Common Shares pursuant to the acquisition of Opticann (Note 22) and Purefarma (Note 15(a)), and the derivative liabilities payable in Heritage Common Shares (Note 16(b)).

25. Fair value of financial instruments

Assets recorded at fair value in the statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities;

Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly; and

Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Financial instruments are measured either at fair value or at amortized cost. The table below lists the valuation methods used to determine the fair value of each financial instrument.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

25. Fair value of financial instruments (continued)

Financial instruments measured at fair value	
Convertible promissory note receivable	Amount due on demand (Level 3)
Other investments	Market value (Level 3)
Note receivable	Market value (Level 3)
Derivative liabilities	Market value (Level 3) or Black-Scholes model (Level 3)
Contingent consideration payable	Discounted cash flow (Level 3) or Black-Scholes model (Level 3)
Financial instruments measured at amortized cost	
Cash; Short-term investments; Accounts receivable; Other current assets; Accounts payable and accrued liabilities	Carrying amount (approximates fair value due to short-term nature)
Long-term debt	Carrying value at the effective interest rate which approximates fair value

During the three and nine months ended July 31, 2022, there were no transfers of amounts between levels (during the three and nine months ended July 31, 2021 – no transfers between levels).

26. Entity-wide disclosures

The Company's trade net revenue for the three and nine months ended July 31, 2022 and July 31, 2021 was all generated domestically (Canada) and is comprised of the following:

	Three months ended July 31,		Nine months ended July 31,	
	2022	2021	2022	2021
Net revenue from sale of Heritage branded products	\$ 7,495,885	\$ 4,312,712	\$ 21,528,280	\$ 8,511,796
Net revenue from sale of White Label products	-	1,602	-	798,572
Net revenue from provision of services	-	-	-	99,737
	\$ 7,495,885	\$ 4,314,314	\$ 21,528,280	\$ 9,410,105

During the three and nine months ended July 31, 2022, the Company earned 89% and 86% of its total trade revenue from five major customers, respectively (during the three and nine months ended July 31, 2021 – 93% and 88% from five major customers, respectively).

27. Operating segment information

During the three and snine months ended July 31, 2022 and July 31, 2021, the Company identified a single reportable operating segment.

HERITAGE CANNABIS HOLDINGS CORP.
Notes To Interim Condensed Consolidated Financial Statements
For The Three and Nine Months Ended July 31, 2022 and July 31, 2021
(Stated in Canadian Dollars, Unaudited)

28. Capital management

The Company manages its cash, short-term investments, common shares, stock options and share purchase warrants as capital. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of a cannabis production business and to maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk level.

The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may attempt to issue new shares, issue new debt, acquire or dispose of assets or adjust the amount of cash and short-term investments on hand.

In order to facilitate the management of its capital requirements, the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. The annual and updated budgets are approved by the Board of Directors.

In order to maximize ongoing production efforts, the Company does not pay out dividends. The Company's investment policy is to invest its short-term excess cash in highly liquid short-term interest-bearing investments, selected with regards to the expected timing of expenditures from continuing operations.

Management considers its approach to capital management to be appropriate given the relative size of the Company. There were no changes in the Company's approach to capital management during the period.

29. Subsequent events

(a) Expiry of option

On August 16, 2022, 2,000,000 options expired unexercised.

(b) Purchase of NCI and settlement of contingent consideration issued in Voyage acquisition

On September 15, 2022, the Company paid \$50,000 in cash and issued 2,000,000 Heritage Common shares as total consideration for its purchase of 500 common shares and 400,000 preferred shares in Voyage from the non-controlling shareholder. As a result, the entire cash-settled contingent consideration payable issued in Voyage acquisition was settled, and the Company increased its interest in Voyage and Mainstrain Market Ltd. from 75% to 100%.

(c) Settlement of contingent consideration issued in Purefarma acquisition

On September 16, 2022, the Company entered into a settlement agreement with the former shareholders of Purefarma to settle all the outstanding obligations of the Company to the former shareholders of Purefarma pursuant to the terms of a share exchange agreement and share purchase agreement each dated December 7, 2018. In satisfaction of all claims related to earn-out share obligations and contingent cash payment obligations described in Note 15(a) and 15(b), the former shareholders of Purefarma directed the Company to issue 14,728,762 common shares to its corporate shareholder, 1187940 B.C. Ltd.